ARID1A, ARID1B, and ARID2 Mutations Serve as Potential Biomarkers for Immune Checkpoint Blockade in Patients With Non-Small Cell Lung Cancer

Worldwide, non-small cell lung cancer (NSCLC) has the highest morbidity and mortality of all malignancies. The lack of responsiveness to checkpoint inhibitors is a central problem in the modern era of cancer immunotherapy, with the rapid development of immune checkpoint inhibitors (ICIs) in recent y...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Guangsheng, Shi, Ruifeng, Li, Yongwen, Zhang, Zihe, Xu, Songlin, Chen, Chen, Cao, Peijun, Zhang, Hongbing, Liu, Minghui, Pan, Zhenhua, Liu, Hongyu, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426508/
https://www.ncbi.nlm.nih.gov/pubmed/34512623
http://dx.doi.org/10.3389/fimmu.2021.670040

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426508/
https://www.ncbi.nlm.nih.gov/pubmed/34512623
http://dx.doi.org/10.3389/fimmu.2021.670040

Ejemplares similares